Statement Regarding the Termination of Sanofi’s Proposed …
On December 11, 2023, the FTC sued to block Sanofi’s acquisition of an exclusive license to Maze’s Phase 2-ready developmental drug—a glycogen synthase 1 inhibitor called MZE001— …
News & Press - Maze Therapeutics
Nov 13, 2024 · Maze Therapeutics Reports Positive First-in-Human Data from Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney …
Maze lands new partner for Pompe drug, after Sanofi pact came …
May 10, 2024 · Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi, five months after a challenge from the Federal Trade Commission caused Sanofi to …
Maze CEO ‘disappointed’ in Sanofi decision to end partnership
Dec 12, 2023 · W hen Sanofi terminated its partnership with Maze Therapeutics this week to develop an experimental drug for Pompe disease, Maze CEO Jason Coloma did not learn the …
FTC, in unusual move, leads Sanofi to terminate a drug research deal
Dec 12, 2023 · Sanofi terminated a licensing deal with biotechnology company Maze Therapeutics Monday after the Federal Trade Commission filed a lawsuit alleging that the …
News Archive | Maze Therapeutics
Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for …
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing
Jan 7, 2025 · (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public …
Maze Therapeutics Announces Oversubscribed $115 Million …
Dec 3, 2024 · MZE829, an oral, APOL1 inhibitor, is being evaluated as a treatment for APOL1 kidney disease (AKD), including in patients with focal segmental glomerulosclerosis (FSGS), …
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
May 1, 2023 · In a deal announced Monday, Sanofi will acquire rights to develop and commercialize Maze’s drug candidate MZE001, which is slated to begin a Phase 2 study later …
Kidney disease drugmaker Maze files for IPO | BioPharma Dive
Jan 8, 2025 · Maze Therapeutics on Tuesday filed plans for an initial public offering that could become the biotechnology sector’s first of the year, depending on how quickly the deal comes …